A double-blind, placebo controlled evaluation of the efficacy, safety and tolerability of BEMA [BioErodible MucoAdhesive] fentanyl in the treatment of breakthrough pain in cancer subjects
Phase of Trial: Phase III
Latest Information Update: 25 Nov 2009
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Sponsors BioDelivery Sciences International
- 25 Nov 2009 Full and final results available in Annals of Oncology, published in advance online.
- 03 Jun 2008 Results were presented at the 44th Annual Meeting of the American Society of Clinical Oncology.
- 09 May 2008 Results presented at the American Pain Society Annual Meeting held in May 2008.